Results 101 to 110 of about 39,201 (181)

Remdesivir triphosphate as a substrate of human PrimPol

, 2023
Trabajo presentado en el 6th DNA Polymerases meeting, celebrado en Stockholm (Suecia) del 22 al 25 de mayo de 2022.Remdesivir is a broad-spectrum antiviral drug which has been recently approved for its emergency use to treat COVID-19.
Jiménez-Juliana, Marcos, Martínez-Jiménez, María I., Blanco Dávila, Luis   +2 more
core  

Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants

Clinical and Translational Science
Remdesivir is an intravenous antiviral approved worldwide for the treatment of COVID‐19 in adults and children. Remdesivir, as a prodrug inhibitor of RNA polymerase, undergoes intracellular activation to form the active metabolite along with 2 inactive ...
Jack Chang, Aryun Kim, Rita Humeniuk, Naveed A. Shaik, Helen Winter, Chi‐Chi Peng, Deqing Xiao, Mazin Abdelghany, Joe Llewellyn, Santosh Davies, Kandace Golden, Shuguang Chen, Robert H. Hyland, Luzelena Caro   +13 more
doaj   +1 more source

Remdesivir como tratamiento para COVID-19 [PDF]

, 2021
Introduction: The SARS-CoV-2 coronavirus was initially detected at the end of 2019, there is no specific drug established for the treatment and due to its homology with the SARS virus, remdesivir has been considered as a therapeutic option.
Bustillos, Alberto, Yépez, Solmayra
core  

Percentage of laboratory values imputed by dexamethasone receipt for remdesivir and non-remdesivir groups.

For the group of patients not receiving remdesivir, the percentage of each laboratory value which was imputed, by control group (A) and treatment (B).
Justin F. Rousseau (18196027), Richard Zhou (9524030), Kaitlyn E. Johnson (7134950), Paul J. Rathouz (13208130)   +3 more
core   +1 more source

Assessing the effect of remdesivir alone and in combination with corticosteroids on time to death in COVID-19: A propensity score-matched analysis

Journal of Clinical Virology Plus
Background: This study aimed to evaluate the impact of remdesivir, alone or in combination with corticosteroids, on the time to death in COVID-19 patients. Methods: This retrospective cohort study was conducted between March 20, 2020, and March 18, 2021,
Mohamad Amin Pourhoseingholi, Mehdi Azizmohammad Looha, Saba Ilkhani, Hamidreza Hatamabadi, Amir Sadeghi, Seyed Amir Ahmad Safavi-Naini, Kamran Heidari, Nazanin Taraghikhah, Mohammad Mahdi Fallah, Reyhaneh Kalantar, Nariman Naderi, Romina Esbati, Nastaran Ebrahimi, Ali Solhpour, Tannaz Jamialahmadi, Amirhossein Sahebkar   +15 more
doaj   +1 more source

Investigation of the nephrotoxicity of remdesivir \(in\) \(vitro\)

Aufgrund von Nierenschädigung im Tiermodell und klinischen Sicherheitsbedenken bezüglich der Anwendung von Remdesivir bei Covid-19-Patienten mit der Gefahr von Nierenfunktionsstörung bis hin zum Nierenversagen im Vergleich zu anderen antiviralen ...
Breunig, Leonie
core   +1 more source

Remdesivir inhibits endothelial activation and atherosclerosis by coupling TAL1 to TRAF6

Journal of Translational Medicine
Background Atherosclerosis is characterized by complex pathological processes, including endothelial dysfunction and inflammation. The underlying pathogenic mechanisms have been well elucidated; however, effective treatments are yet to be validated.
Hanning Zhang, Ruru Li, Qianqian Huo, Li Li, Min Li, Shunxin Hu, Changjie Ren, Zongyin Wu, Chenghu Zhang   +8 more
doaj   +1 more source

Remdesivir for the treatment of COVID-19 — Final report

, 2020
BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.
Kalil, A.C., Dierberg, K., Fätkenheuer, G., Dodd, L.E., Beigel, J.H., Makowski, M., Chu, H.Y., Green, M., Babiker, A.G., for the ACTT-1 Study Group Members, Lye, D.C., Atmar, R.L., Neaton, J.D., Finberg, R.W., de Castilla, D.L., Paredes, R., Bonnett, T., Ohmagari, N., Benfield, T., Pett, S., Hohmann, E., Tomashek, K.M., Luetkemeyer, A., Creech, C.B., Sweeney, D.A., Short, W.R., Lundgren, J., Nayak, S., Mehta, A.K., Ruiz-Palacios, G.M., Hsieh, L., Oh, M.-D., Kortepeter, M.G., Touloumi, G., Zingman, B.S., Osinusi, A., Tapson, V., Lane, H.C., Kline, S., Patterson, T.F., Burgess, T.H.   +40 more
core   +1 more source

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance

Viruses
Various SARS-CoV-2 remdesivir resistance-associated substitutions (RAS) have been reported, but a comprehensive comparison of their resistance levels is lacking.
Carlota Fernandez-Antunez, Line A. Ryberg, Kuan Wang, Long V. Pham, Lotte S. Mikkelsen, Ulrik Fahnøe, Katrine T. Hartmann, Henrik E. Jensen, Kenn Holmbeck, Jens Bukh, Santseharay Ramirez   +10 more
doaj   +1 more source

The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load

Scientific Reports
The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load.
Petr Waldauf, Ivana Jurisinova, Eva Svobodova, Michaela Diblickova, Tomas Tencer, Jan Zavora, Gabriela Smela, Lenka Kupidlovska, Vaclava Adamkova, Marta Fridrichova, Karolina Jerabkova, Jakub Mikes, Frantisek Duska, Ladislav Dusek, Martin Balik   +14 more
doaj   +1 more source